Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, People's Republic of China.
Med Oncol. 2012 Dec;29(5):3029-34. doi: 10.1007/s12032-012-0292-y. Epub 2012 Jul 6.
The overexpression of β-tubulin III (TUBB3) in tumor tissues was reversely related with the efficacy of paclitaxel and clinical outcome in different cancers. In this study, we aimed to investigate the association between serum levels of TUBB3 and clinical outcome in advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine. One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study. Serum samples from 32 healthy individuals were used as controls. TUBB3 expression level in advanced gastric cancer was significantly higher than that in healthy control group (31.6 ± 17.8 ng/mL vs. 16.9 ± 3.8 ng/mL, p < 0.001). For all patients, the clinical benefit rate (CBR), median progression-free survival (PFS), and overall survival (OS) were 55.6 %, 179 and 306 days, respectively. The CBR, median PFS, and OS in patients with low (n = 27) and high levels (n = 101) of TUBB3 were 95.8 %/45.1 % (low vs. high, p < 0.001), 190 days/166 days (p = 0.064), and 360 days/297 days (p = 0.023), respectively. Cox multivariate regression analysis demonstrated that the serum levels of TUBB3 were an independent prognostic factor for advanced gastric cancer patients (HR = 1.950; 95 % CI, 1.242-3.062; p = 0.004). This study indicated that low levels of TUBB3 in serum could predict better response and survival for advanced gastric cancer patients receiving paclitaxel plus capecitabine, which could be used to select patients who would benefit from this regimen.
β-微管蛋白 III（TUBB3）在肿瘤组织中的过度表达与不同癌症中紫杉醇的疗效和临床结局呈负相关。本研究旨在探讨接受紫杉醇联合卡培他滨一线治疗的晚期胃癌患者血清 TUBB3 水平与临床结局的相关性。
北京大学肿瘤医院 2006 年 12 月至 2010 年 10 月收治的 128 例接受紫杉醇联合卡培他滨一线治疗的晚期胃癌患者纳入本研究，同期 32 例健康体检者作为对照。结果显示，晚期胃癌患者 TUBB3 表达水平明显高于健康对照组（31.6±17.8ng/ml 比 16.9±3.8ng/ml，P<0.001）。所有患者的临床获益率（CBR）、中位无进展生存期（PFS）和总生存期（OS）分别为 55.6%、179 天和 306 天。TUBB3 低表达（n=27）和高表达（n=101）患者的 CBR、中位 PFS 和 OS 分别为 95.8%/45.1%（低 vs.高，P<0.001）、190 天/166 天（P=0.064）和 360 天/297 天（P=0.023）。Cox 多因素回归分析表明，血清 TUBB3 水平是晚期胃癌患者的独立预后因素（HR=1.950；95%CI，1.242~3.062；P=0.004）。
该研究表明，血清 TUBB3 水平低可预测接受紫杉醇联合卡培他滨治疗的晚期胃癌患者有更好的反应和生存，可用于选择可能从该方案中获益的患者。
